Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer
Open Access
- 7 June 2012
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 61 (12), 2251-2259
- https://doi.org/10.1007/s00262-012-1289-2
Abstract
Purpose To determine the long-term efficacy of adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells for locally advanced gastric cancer patients. Experimental design One hundred and fifty-one patients with stage III/IV gastric cancer who had undergone gastrectomy were enrolled, assigned to two groups (immunotherapy group versus no immunotherapy group/or control group), and followed. Results The 5-year overall survival (OS) and 5-year disease-free survival (DFS) rates for immunotherapy versus control group were 32.4 versus 23.4 % (P = 0.071) and 28.3 versus 10.4 % (P = 0.044), respectively. For patients with intestinal-type tumors, the 5-year OS and DFS rates were significantly higher for immunotherapy (OS, 46.8 vs. 31.4 % and P = 0.045; DFS, 42.4 vs. 15.7 % and P = 0.023). In the immunotherapy group, the mean CD3+ level, CD4+ level, and CD4+/CD8+ ratio increased from 50.8, 26.5, and 0.9 %, respectively, at baseline to 62.6, 35.0, and 1.4 %, respectively, 1 week after the first CIK-cell treatment, returned to baseline after 2 months, and maintained a higher level (60.7 ± 8.2 %, 34.2 ± 7.1 %, and 1.3 ± 0.3 %, respectively) 2 months after 3 cycles of immunotherapy. Conclusions Adjuvant immunotherapy with CIK cells prolongs DFS in patients with locally advanced gastric cancer and significantly improves OS in patients with intestinal-type tumors. Intestinal-type tumors could be selected as an important indication for CIK-cell therapy. This treatment may help improve T-lymphocyte subset distribution and improve the host’s immune functions, but multiple cycles are necessary for long-term therapeutic efficacy.Keywords
This publication has 44 references indexed in Scilit:
- Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)Zeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Developments in clinical cell therapyCytotherapy, 2010
- Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanismsJournal of Leukocyte Biology, 2006
- Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)Annals of Oncology, 2005
- Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancerGastric Cancer, 2004
- Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1Journal of Clinical Oncology, 2003
- Propagation of large numbers of T cells with natural killer cell markersBritish Journal of Haematology, 1994
- Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancerThe Lancet, 1994
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Need for lmmunologic Stimulators During lmrnunosuppression Produced by Major Cancer SurgeryAnnals of Surgery, 1985